ANPEP expression is upregulated in the plasma of patients with nonalcoholic fatty liver disease (NAFLD) and cirrhosis, suggesting that it may be involved in the progression of NAFLD and may serve as a potential drug target (Niu et al., 2019). Here, ANPEP is linked to metabolic dysfunction-associated steatotic liver disease.